Wild-type RAS signaling is an essential therapeutic target in <i>RAS</i> -mutated cancers
Nancy E. Sealover(Uniformed Services University of the Health Sciences), Robert L. Kortum(Uniformed Services University of the Health Sciences)
Cited by 3
Related Papers
A Phospholipase C-γ1–Independent, RasGRP1-ERK–Dependent Pathway Drives Lymphoproliferative Disease in Linker for Activation of T Cells–Y136F Mutant Mice
|The Journal of Immunology|2012|17
In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies
|bioRxiv (Cold Spring Harbor Laboratory)|2023|2